Literature DB >> 21701538

Tubal origin of 'ovarian' low-grade serous carcinoma.

Jie Li1, Nisreen Abushahin, Shujie Pang, Li Xiang, Setsuko K Chambers, Oluwole Fadare, Beihua Kong, Wenxin Zheng.   

Abstract

Ovarian low-grade serous carcinomas are thought to evolve in a stepwise fashion from ovarian epithelial inclusions, cystadenomas, and borderline tumors. The current study was designed to gain insight into the origins of low-grade serous carcinomas (tubal versus ovarian) by comparatively evaluating the morphologic (secretory and ciliated cell distribution) and immunophenotypic (using antibodies to PAX8, tubulin, calretinin, and Ki67) attributes of its putative precursor lesions, the normal tubal epithelium, and the overt malignancy. A total of 226 adnexal tissues from 178 patients were studied, including 98 adnexae removed for non-neoplastic indications, 48 serous cystadenomas, 42 serous borderline tumors, and 38 low-grade serous carcinomas. Normal distal tubal epithelium comprised an admixture of PAX8+/tubulin- secretory cells and PAX8-/tubulin+ ciliated cells with a proliferative index of ∼3%. The vast majority of ovarian surface epithelia displayed a mesothelial phenotype (calretinin+/PAX8-/tubulin-) and low proliferative index (0% (12 per 1000)), although 4% of cases also displayed foci with tubal phenotype (calretinin-/PAX8+/tubulin+). In contrast, most (78%) of the ovarian epithelial inclusions displayed a tubal phenotype and had a significantly higher proliferative index (1%) than ovarian surface epithelium, indicating that in most cases, the ovarian surface epithelium and ovarian epithelial inclusions are of different lineages. There was a progressive decrease in the population of ciliated cells, as evidenced by increasing secretory/ciliated cell ratio, from ovarian epithelial inclusions/cystadenomas to borderline tumors to low-grade serous carcinoma, indicating that the latter is a clonal expansion of secretory cells. Overall, the findings make a strong argument that the ovarian epithelial inclusions with a tubal phenotype is likely derived from fallopian tube through an intraovarian endosalpingiosis rather than through Mullerian metaplasia from ovarian surface epithelium. Genetic and molecular studies are needed to further confirm this finding as tubal origination of ovarian serous cancers will have a significant impact on ovarian cancer prevention and management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21701538     DOI: 10.1038/modpathol.2011.106

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  47 in total

1.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

Review 2.  Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.

Authors:  Yiying Wang; Maggie Mang; Yue Wang; Lijie Wang; Robert Klein; Beihua Kong; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.

Authors:  Christine Gruessner; Angelika Gruessner; Katherine Glaser; Nisreen AbuShahin; Yi Zhou; Cynthia Laughren; Heather Wright; Samantha Pinkerton; Xiaofang Yi; Jha'nae Stoffer; Masoud Azodi; Wenxin Zheng; Setsuko K Chambers
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-20

4.  Characterization of the immune cell repertoire in the normal fallopian tube.

Authors:  Laura Ardighieri; Silvia Lonardi; Daniele Moratto; Fabio Facchetti; Ie-Ming Shih; William Vermi; Robert J Kurman
Journal:  Int J Gynecol Pathol       Date:  2014-11       Impact factor: 2.762

5.  Reversal of tubo-ovarian atypical epithelial patterns after cessation of ovarian stimulation by letrozole.

Authors:  Ahmed A M Abdel-Hamid; Yaser Mesbah; Mona F M Soliman
Journal:  Int J Exp Pathol       Date:  2016-09-01       Impact factor: 1.925

6.  Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells.

Authors:  Sarah J Harmych; Jay Kumar; Mesa E Bouni; Deborah N Chadee
Journal:  Exp Cell Res       Date:  2020-07-07       Impact factor: 3.905

7.  PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.

Authors:  Angela Russo; Austin A Czarnecki; Matthew Dean; Dimple A Modi; Daniel D Lantvit; Laura Hardy; Seth Baligod; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

8.  Tubal origin of ovarian low-grade serous carcinoma.

Authors:  Chenglu Chen; Jie Li; Guang Yao; Setsuko K Chambers; Wenxin Zheng
Journal:  Am J Clin Exp Obstet Gynecol       Date:  2013-12-15

9.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

10.  Inhibitory role of prohibitin in human ovarian epithelial cancer.

Authors:  Lin Jia; Jian-Min Ren; Yi-Ying Wang; Yu Zheng; Hui Zhang; Qing Zhang; Bei-Hua Kong; Wen-Xin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.